Parabilis Q2 2026: $52.5M Net Loss, $1.12B Cash Runway into 2030

summarizeSummary

Parabilis Medicines' first 10-Q as a public company shows a $52.5 million Q2 net loss, $1.12 billion in cash providing runway into 2030, and initial revenue recognition from the Regeneron collaboration.

check_boxKey Events · Earnings and Guidance · PBLS

• Q2 Net Loss of $52.5M

  Net loss was $52.5 million for Q2 2026, up from $34.8 million in Q2 2025, driven by a 30.7% increase in R&D expense to $39.4 million and an 82.3% increase in G&A to $11.7 million.

• $1.12B Cash Runway into 2030

  Cash, cash equivalents and marketable securities totaled $1.12 billion as of June 30, 2026, which management expects to fund operations into 2030.

• Regeneron Collaboration Revenue Begins

  Recognized $0.1 million in collaboration revenue from the Regeneron agreement, with $41.5 million in deferred revenue on the balance sheet to be recognized through at least 2029.

• ARTBIO Collaboration Terminated

  ARTBIO sent notice of intent to opt out of all research programs on April 16, 2026; Parabilis sent termination notice on May 26, 2026. No eligible costs were incurred in H1 2026.

auto_awesomeAnalysis · PBLS · Life Sciences

Parabilis Medicines reported its first quarterly results as a public company, posting a Q2 net loss of $52.5 million on $0.1 million in collaboration revenue. The company holds $1.12 billion in cash and marketable securities, which management expects to fund operations into 2030. R&D spending rose 30.7% year-over-year to $39.4 million, driven by zolucatetide clinical development and headcount growth. The Regeneron collaboration contributed $41.5 million in deferred revenue, while the ARTBIO collaboration was terminated in May 2026. The 10-Q also details the June 2026 IPO mechanics, including the 1-for-1.5389 reverse split and conversion of all preferred stock.